In our chosen profession, patients come first. For care to be optimized, work environments need to be safe and supportive. We believe this is possible through productive discussions held in good faith between a workforce and its employers, to reach a fair and much-needed resolution to the grievances of America’s pharmacists.

Our profession is experiencing unprecedented rates of burnout and even a great migration of oncology pharmacists away from patient care roles. This problem is so endemic that HOPA has established a Wellness Task Force to help combat burnout among our members. And still, more can be done.

We know that addressing the wide, systemic concerns among pharmacists, pharmacy technicians, and other healthcare workers does not come with a simple solution. But we also know pharmacists and pharmacies have a shared goal of providing the best patient care possible.

Some initial promising steps have been taken, and we hope this continues for the good of patient care. We support all pharmacists, regardless of setting or specialty, and hope for a swift and satisfactory resolution to industrial actions being taken today.

oncology pharmacist at work with patients
Advocacy

Time to Complete Oncology Pharmacist Tasks: A Joint Opinion of HOPA and American College of Clinical Pharmacy's Hematology/Oncology Practice and Research Network

HOPA and the Hematology/Oncology Practice and Research Network (PRN) of the ACCP published research producing the first comprehensive consensus statements on the average time for a U.S.-based oncology pharmacist to complete common care-related tasks.

HOPA logo
Advocacy

Together We Can Save Cancer Research - and Lives

In the past two decades, extraordinary progress has been made in the fight against cancer. However, with Congress determined to reduce federal spending, entire cancer research, prevention, and surveillance programs are on the verge of elimination.

Advocacy

HOPA Signs Letter in Support of Cancer Research Funding and Infrastructure

Thirty-three organizations have signed a letter in support of cancer research funding amid Executive Orders that threaten the stability of research infrastructure.